← SynDRA

SORAFENIB

SynDRA canonical compound SYN0005358 — structure-anchored drug synonym record

All known targets

• KDR
• KIT
• PDGFRB
• RAF1
• RET
• BRAF
• FLT3
• DDR2
• FGFR1
• FLT1
• FLT4
• CDK19

Mechanisms of action (all sources)

• KIT INHIBITOR
• RAF inhibitor
• FLT3 INHIBITOR
• PDGFR inhibitor
• VEGFR inhibitor
• RET tyrosine kinase inhibitor
• RAF1 INHIBITOR
• Serine/threonine-protein kinase RAF inhibitor
• PDGFRB INHIBITOR
• Platelet-derived growth factor receptor beta inhibitor
• Stem cell growth factor receptor inhibitor
• Tyrosine-protein kinase receptor FLT3 inhibitor

Drug classes

• Protein Kinase Inhibitors
• Antineoplastic Agents
• Enzyme Inhibitors
• Kinase Inhibitor

ATC classes

• L01E · PROTEIN KINASE INHIBITORS

Cross-references

• PubChem CID: 216239
• ChEMBL: CHEMBL1336
• DrugBank: DB00398
• ChEBI: CHEBI:50924
• KEGG: D06272
• RxNorm: 495881
• PDB: BAX
• Wikipedia: Sorafenib
• TTD: D0W5HK
• LINCS BRD: BRD-K23984367

Synonyms

• BAY 43-9006
• BAY-545-9085
• sorafenib tosilate
• nexavar
• sorafenib tosylate
• BAY-43-9006
• Nexavar
• Sorafenibum
• Sorafenib [INN]
• Nexavar (TN)
• Sorafenib (INN)
• N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
• N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
• N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
• 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
• 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
• 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
• 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
• 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
• 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
• 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
• 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
• 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
• Sorafenib (Pan-TK inhibitor)
• 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N-METHYLPICOLINAMIDE
• sorafenibum
• Sorafenib free base
• 284461-73-0 (free base)
• MFCD06411450
• 9ZOQ3TZI87
• CHEMBL1336
• DTXSID7041128
• CHEBI:50924
• 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-
• Sorafenib (Nexavar)
• Donafenib (Sorafenib D3)
• 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
• BAX

Reported adverse events

• Asthenia
• Fatigue
• Lymphopenia
• Stomatitis
• Thrombocytopenia
• Abdominal pain
• Constipation
• Epistaxis
• Erythema
• Gastrointestinal perforation
• Headache
• Hyperkeratosis